We narrowed to 19,689 results for: CAL

#169256-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-Soma-jGCaMP8s (#169256). In addition to the viral particles, you will also receive purified AAV-hSyn-Soma-jGCaMP8s plasmid DNA. hSyn-driven expression of soma-targeted calcium sensor GCaMP8s (more sensitive). These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

July 21, 2023

Academic Institutions and Nonprofits only

#99039-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

May 15, 2019

Academic Institutions and Nonprofits only

#111068-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-dLight1.2 (#111068). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.2 plasmid DNA. Synapsin-driven expression of dLight1.2 dopamine sensor. This sensor has a slightly increased dynamic range and is better for 2P imaging in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Feb. 25, 2021

Academic Institutions and Nonprofits only

#104495-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE (#104495). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE plasmid DNA. CAG-driven, Cre-dependent GCaMP7s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Aug. 24, 2020

Academic Institutions and Nonprofits only

#135635-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#112677-AAV5

Ready-to-use AAV5 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Aug. 26, 2019

Academic Institutions and Nonprofits only

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#128589-AAV8

Ready-to-use AAV8 particles produced from AAV-Syn-FLPX-rc [ChrimsonR-tdTomato] (#128589). In addition to the viral particles, you will also receive purified AAV-Syn-FLPX-rc [ChrimsonR-tdTomato] plasmid DNA. Syn-driven, Flp-dependent ChrimsonR-tdTomato expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 14, 2022

Academic Institutions and Nonprofits only